The US health regulator has provided its final approval to Glenmark Pharmaceuticals for Potassium Chloride Extended Release Tablets that are used in the treatment of low levels of potassium in blood.

It has said in a BSE filing that “Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Potassium Chloride Extended Release Tablets USP, 10mEq (750 mg) and 20mEq (1500mg).”

The tablet is a generic version of K-Dur extended release tablets of Merck Sharp and Dohme Corp.

Read EquityPandit’s Nifty Pharma Outlook for this week